Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares. J&J “kicked off MedTech 4Q24 earnings season on an overall-positive note” with about 6% organic sales growth that was above the firm’s and Street’s estimates. However, the company’s initial 2025 financial guidance “fell below our previous thinking” at the midpoints, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target lowered to $159 from $160 at BofA
- Johnson & Johnson price target lowered to $163 from $175 at Morgan Stanley
- Johnson & Johnson price target lowered to $158 from $160 at Bernstein
- Johnson & Johnson publishes nipocalimab study results in The Lancet Neurology
- Johnson & Johnson price target lowered to $152 from $166 at Wells Fargo